Virtual screening to facilitate structure-based drug design
Metabolomics Australia (MA): focused on providing customised service for small molecule analysis, access to world class expertise, analytical technologies and bioinformatics. Breadth of capability across biotechnology, diagnostics, environmental, agriculture, food/beverage and biomedical sciences. Providing specific detection, quantification services and catering to complex investigations and systems wide analyses. ENABLING INNOVATION.
The HTCS Facility houses a Lead Discovery library currently containing ~200,000 compounds and robotics platforms to screen these small molecule chemical entities against biological targets of interest for drug discovery or for chemical biology outcomes
Encompasses and uses the CSIRO Biomolecular Interaction Facility and the CSIRO Bio21 Crystallisation Centre to screen libraries of fragments as the first step towards rational drug design
The Drug Delivery Disposition and Dynamics (D4) Theme at the Monash Institute of Pharmaceutical Sciences provides expertise and infrastructure in drug formulation and drug delivery system design and assessment and evaluation of drug formulations/delivery systems in pre-clinical animal models.
Burnet Antiviral Screening facility offers testing of chemical agents for their inhibitory activity against viruses including HIV and herpes simplex type 1 and 2 in cell culture based assays.
The Australian Synchrotron produces powerful beams of light that can be used to examine the atomic and molecular detail of a wide range of materials.
AdAlta has significant expertise and proprietary libraries that will enable the discovery and identification of lead candidates. AdAlta can rapidly identify high quality binders from it's i-body or shark antibody libraries.